Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
Recruiting
Observational Study
Prostate Cancer
Castrate Resistant Prostate Cancer
BRCA Mutation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Male
- Study type
- Observational
- Participants needed
- 3,000 (estimated)
- Sponsor
- Santa Chiara Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice
Exclusion Criteria:
Olaparib treatment in a clinical trial
Contacts